Picture of Biocure Technology logo

CURE Biocure Technology Share Price

0.000.00%
ca flag iconLast trade - 00:00
EnergySpeculativeMicro Cap

Momentum

Relative Strength (%)
1m-27.34%
3m-19.89%
6m-52.97%
1yr-79.66%
Volume Change (%)
10d/3mn/a
Price vs... (%)
52w High-82.22%
50d MA-39.12%
200d MA-74.67%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-31.87%
Return on Equity-39.24%
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
30th Sep 201030th Sep 2011
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2010 / 2011

Blurred out image of Biocure Technology EPS forecast chart

Profile Summary

Biocure Technology Inc. is a Canada-based biotech company that is developing its CAR-T cell therapy for leukemia, lung, breast and pancreatic cancer. The Company focuses on developing and commercializing various biopharmaceutical technologies relating to uses of recombinant and ranibizumab. The Company in the process of pre-clinical trials of five biosimilar products in South Korea, including Interferon Beta 1b, PEG- Filgrastim as well as Ranibizumab. Interferon Beta 1b is used for treating relapsing forms of multiple sclerosis (MS). Filgrastim is used to treat neutropenia, a lack of certain white blood cells caused by bone marrow transplants, chemotherapy, and other conditions. Ranibizumab is used for treating macular degeneration and is also used to treat a type of eye problem known as macular edema, as well as certain eye problems caused by diabetes. The Company is also engaged in a mineral exploration property project through a limited partnership.

Directors

    Last Annual
    September 30th, 2009
    Last Interim
    December 31st, 2009
    Incorporated
    August 24th, 2007
    Public Since
    March 27th, 2008
    Sector
    Uranium
    Industry
    Energy
    Exchange
    ca flag iconCanadian Securities Exchange
    Shares in Issue
    4,000,000

    CURE Share Price Performance

    Similar to CURE

    Picture of American Future Fuel logo

    American Future Fuel

    ca flag iconCanadian Securities Exchange

    Picture of Appia Rare Earths & Uranium logo

    Appia Rare Earths & Uranium

    ca flag iconCanadian Securities Exchange

    Picture of First Uranium Resources logo

    First Uranium Resources

    ca flag iconCanadian Securities Exchange

    Picture of Labrador Uranium logo

    Labrador Uranium

    ca flag iconCanadian Securities Exchange

    Picture of Madison Metals logo

    Madison Metals

    ca flag iconCanadian Securities Exchange

    FAQ

    Or unlock with your email

    Or unlock with your email